DEF 14A: Qualigen Therapeutics Seeks Stockholder Approval for Reverse Stock Split, Director Elections, and More at 2024 Annual Meeting

Qualigen Therapeutics is holding its 2024 Annual Meeting of Stockholders on October 25, 2024, to vote on key proposals including a reverse stock split, director elections, and ratification of the company's independent accounting firm.

Summary

• Qualigen Therapeutics will hold its 2024 Annual Meeting of Stockholders on October 25, 2024, at 10:00 a.m. Pacific Daylight Time in Carlsbad, California.
• Stockholders will vote on six proposals, including the election of five directors, ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approval of a reverse stock split.
• The reverse stock split would be within a range of 1-for-10 to 1-for-50, with the exact ratio to be determined by the Board of Directors.
• Stockholders will also vote on a proposal to adjourn the meeting if necessary to solicit additional proxies for the reverse stock split.
• Additionally, they will vote on approving the issuance of more than 20% of the company's common stock to Alpha Capital Anstalt and Yi Hua Chen under existing convertible debentures and warrants.
• Finally, there will be a non-binding, advisory vote on the compensation of the company's named executive officers.
• The record date for determining stockholders eligible to vote is September 6, 2024.
• As of the record date, there were 27,022,039 shares of common stock outstanding.

Sentiment

Score: 4

Explanation: The document presents a mix of positive and negative information. While the company is taking steps to address its Nasdaq listing issues and has implemented corporate governance measures, the delisting notice and financial losses contribute to a negative sentiment.

Positives

• The company is taking steps to address its non-compliance with Nasdaq's minimum bid price requirement through the proposed reverse stock split.
• The board of directors is actively involved in risk oversight through its committees.
• The company has a code of business conduct and ethics in place.
• The company is utilizing a U.S. Securities and Exchange Commission Rule that allows companies to furnish their proxy materials over the Internet rather than in paper form, reducing environmental impact and costs.

Negatives

• The company received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement.
• The company has a history of related party transactions, including dealings with Alpha Capital Anstalt.
• The company has experienced turnover in executive positions, including the resignation of the Chief Medical Officer and the President, Chief Strategy and Operating Officer.
• The company implemented temporary salary reductions for executive officers and directors as part of cost-cutting measures in 2023.

Risks

• Failure to regain compliance with Nasdaq listing standards could result in delisting, leading to decreased liquidity and investor interest.
• The reverse stock split may not result in a sustained increase in the stock price.
• The reverse stock split could lead to some stockholders owning odd lots, which may be difficult to sell.
• The issuance of additional shares to Alpha Capital Anstalt and Yi Hua Chen could dilute existing stockholders' equity.
• The company's reliance on key personnel and dependence on third parties pose risks to its operations.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements through a reverse stock split and other measures. The success of these efforts will determine the company's future ability to remain listed on the exchange.

Management Comments

• On behalf of the board of directors, we would like to express our appreciation for your continued interest in the affairs of Qualigen Therapeutics, Inc.
• Our Board of Directors has determined that having the same person fill both roles is appropriate at this time given the early stage of our business and that separating the roles could add inefficiencies without bringing meaningful advantages for our stockholders.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors. However, the need to maintain Nasdaq listing compliance is a common concern for publicly traded companies, particularly those in the biotechnology sector.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• However, the discussion of executive compensation and corporate governance practices suggests an awareness of prevailing norms and expectations for publicly traded companies.
• The document mentions Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) as the employer of Matthew Korenberg, a director of Qualigen Therapeutics, which provides some context regarding industry experience and affiliations.

Management Changes

Related Party Transactions

• On May 26, 2022, the Company acquired 2,232,861 shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (NanoSynex) from Alpha a related party, in exchange for 350,000 reverse split adjusted shares of the Companys common stock and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Companys common stock at an exercise price of $0.001 per share.
• On December 22, 2022, we entered into a Securities Purchase Agreement with Alpha and in exchange for $3,000,000 in cash (less $50,000 for expense reimbursement) issued to Alpha the 2022 Debenture, plus 2,500,000 common stock warrants exercisable (from June 22, 2023 through June 22, 2028) at $1.65 per share.
• On February 27, 2024, upon our receipt of a cash purchase price payment of $500,000 less expenses, we issued to Alpha an 8% Convertible Debenture (the 2024 Alpha Debenture) in the principal amount of $550,000.
• On April 11, 2024, Alpha assigned the option to Yi Hua Chen (Chen) and Chen exercised the option in full on that date.
• On April 12, 2024, against Chens Option exercise price of $1,000,000 paid to us, we delivered to Chen an 8% Convertible Debenture in the principal amount of $1,100,000, of like tenor as the 2024 Alpha Debenture except for the principal amount; and a common stock purchase warrant to purchase 1,800,032 shares of our common stock, exercisable until February 27, 2029, and otherwise of like tenor as the warrant issued to Alpha on February 27, 2024.

Stakeholder Impact

• Shareholders: The reverse stock split and potential delisting could impact the value of their investment.
• Employees: Delisting could affect employee morale and potentially impact their stock options.
• Customers and Suppliers: The company's financial stability and Nasdaq listing status could influence their confidence in the company.
• Creditors: The company's ability to repay debt could be affected by its financial performance and access to capital.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on October 25, 2024.
• The board of directors will determine the exact ratio for the reverse stock split, if approved.
• The company will file the amendment to the certificate of incorporation to effect the reverse stock split, if approved.
• The company will continue to monitor its stock price and consider other options to regain compliance with Nasdaq listing rules if the reverse stock split is not approved.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, stockholders, directors, Qualigen Therapeutics, executive compensation, Nasdaq, convertible debentures, warrants, Alpha Capital Anstalt, Yi Hua Chen, WithumSmith+Brown, corporate governance